Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

Abstract

Prolyl hydroxylase (PHD) inhibitors stabilize hypoxia inducible factor (HIF), and exert antianemic effect by potentiating erythropoietin (EPO) expression and down-regulation of hepcidin. ZYAN1 is a novel PHD inhibitor under clinical development for the treatment of anemia. The pharmacodynamic effects of acute and chronic dosing of ZYAN1 were assessed in normal and 5/6 nephrectomized Wistar rats. The effect of ZYAN1 was also investigated in cisplatin-induced anemia using C57 mice. Acute treatment with ZYAN1 increased circulating EPO levels (10.3±3.7 and 40.0±8.5 fold rise at 15 and 30 mg/kg, respectively), reticulocyte count (4.2±0.5 and 6.0±0.2 fold rise at 15 and 30 mg/kg, respectively) and stabilized HIF (28% increase at 45 mg/kg) in normal rats. Nephrectomized rats showed similar dose-related pharmacodynamic effects. In a 28-day study in nephrectomized rats, ZYAN1 administered every alternate day, caused increase in hemoglobin (1.9±0.3 and 2.5±0.4 g/dL) and RBC count (10.7±4.0 and 14.0±4.1%) at 15 and 30 mg/kg respectively. In cisplatin-treated mice also an increase in hemoglobin (3.4±0.2 and 5.9±0.2 g/dL) and RBC count (22.5±2.2 and 37.3±1.7%) at 15 and 30 mg/kg respectively was observed. ZYAN1’s effects on hemoglobin and RBC count were distinct from darbepoietin. ZYAN1 demonstrated hematinic potential by combined effects on EPO release and efficient iron utilization. The efficacy of ZYAN1 in disease models of different etiologies suggests that it will be useful in treating wide spectrum of anemia patients.

Key words

novel drug - HIF - hepcidin - CKD - chemotherapy

• References

• 1 McLean E, Cogswell M, Egli I et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr 2009; 12: 444-454
• 2 Campbell K. Anaemia: causes and treatment. Nurs Times 2003; 99: 30-33
• 3 Melosky BL. Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol 2008; 15: S10-S15
• 4 Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5: 627-628
• 5 Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs 2011; 20: 645-656
• 6 Hare GM, Tsui AK, Ozawa S et al. Anaemia: can we define haemoglobin thresholds for impaired oxygen homeostasis and suggest new strategies for treatment?. Best Pract Res Clin Anaesthesiol 2013; 27: 85-98
• 7 Lando D, Gorman JJ, Whitelaw ML et al. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem. 2003; 270: 781-790
• 8 Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472
• 9 Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480
• 10 Smith TG, Talbot NP. Prolyl hydroxylases and therapeutics. Antioxid Redox Signal 2010; 12: 431-433
• 11 Peyssonnaux C, Zinkernagel AS, Schuepbach RA et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-1932
• 12 Virgilli-Lopez G. Roxadustat. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, treatment of anemia. Drugs of the Future 2014; 39: 783-791
• 13 Denny WA. Giving anemia a boost with inhibitors of prolyl hydroxylase. J Med Chem. 2012; 55: 2943-2944
• 14 Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542
• 15 Minamishima YA, Kaelin Jr WG. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 2010; 329: 407
• 16 Bellizzi V, Sabbatini M, Fuiano G et al. The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol Dial Transplant 1998; 13: 2210-2215
• 17 Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int 2009; 75: 682-688
• 18 Flamme I, Oehme F, Ellinghaus P et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One 2014; 9: e111838
• 19 Bernhardt WM, Wiesener MS, Scigalla P et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21: 2151-2156
• 20 Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95: 1650-1659
• 21 Bokemeyer C, Oechsle K, Hartmann JT. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest 2005; 35 (Suppl. 03) 26-31
• 22 Dufour P, Bergerat JP, Eber M et al. Cisplatin-induced anemia: a potential interference with iron metabolism at erythroid progenitors level. Anticancer Drugs 1990; 1: 49-54
• 23 Gafter-Gvili A, Rozen-Zvi B, Vidal L et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013; 52: 18-29